JP2001522783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001522783A5 JP2001522783A5 JP2000516701A JP2000516701A JP2001522783A5 JP 2001522783 A5 JP2001522783 A5 JP 2001522783A5 JP 2000516701 A JP2000516701 A JP 2000516701A JP 2000516701 A JP2000516701 A JP 2000516701A JP 2001522783 A5 JP2001522783 A5 JP 2001522783A5
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- modified botulinum
- modified
- glu
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108030001720 Bontoxilysin Proteins 0.000 description 7
- 229940053031 botulinum toxin Drugs 0.000 description 7
- -1 Glu amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102220283759 rs552880257 Human genes 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/954,302 US6051239A (en) | 1997-10-20 | 1997-10-20 | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| US08/954,302 | 1997-10-20 | ||
| PCT/US1998/021897 WO1999020306A1 (en) | 1997-10-20 | 1998-10-16 | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001522783A JP2001522783A (ja) | 2001-11-20 |
| JP2001522783A5 true JP2001522783A5 (enExample) | 2006-02-16 |
Family
ID=25495232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000516701A Pending JP2001522783A (ja) | 1997-10-20 | 1998-10-16 | 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6051239A (enExample) |
| EP (1) | EP1024827B1 (enExample) |
| JP (1) | JP2001522783A (enExample) |
| KR (1) | KR100594787B1 (enExample) |
| CN (1) | CN1246038C (enExample) |
| AT (1) | ATE355076T1 (enExample) |
| AU (1) | AU756475B2 (enExample) |
| BR (1) | BR9815255A (enExample) |
| CA (1) | CA2306995A1 (enExample) |
| DE (1) | DE69837209T2 (enExample) |
| EE (1) | EE200000536A (enExample) |
| HU (1) | HUP0101017A3 (enExample) |
| IL (1) | IL135743A (enExample) |
| NZ (1) | NZ504549A (enExample) |
| RU (1) | RU2227042C2 (enExample) |
| WO (1) | WO1999020306A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7227010B2 (en) | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| ES2275992T5 (es) * | 2000-02-08 | 2011-05-18 | Allergan, Inc. | Composiciones farmacéuticas de toxina botulínica. |
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| AU2002228887B2 (en) * | 2000-11-06 | 2006-08-24 | United States Army Medical Research And Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20040013687A1 (en) * | 2002-05-31 | 2004-01-22 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| EP1629090B1 (en) | 2002-11-06 | 2014-03-05 | iBio, Inc. | Expression of foreign sequences in plants using trans-activation system |
| US7683238B2 (en) * | 2002-11-12 | 2010-03-23 | iBio, Inc. and Fraunhofer USA, Inc. | Production of pharmaceutically active proteins in sprouted seedlings |
| US7692063B2 (en) * | 2002-11-12 | 2010-04-06 | Ibio, Inc. | Production of foreign nucleic acids and polypeptides in sprout systems |
| NZ540425A (en) * | 2002-12-20 | 2009-03-31 | Botulinum Toxin Res Ass Inc | Pharmaceutical botulinum toxin compositions |
| AU2004209660A1 (en) * | 2003-02-03 | 2004-08-19 | Fraunhofer Usa, Inc. | System for expression of genes in plants |
| US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| AU2005216133A1 (en) * | 2004-02-20 | 2005-09-09 | Fraunhofer Usa, Inc. | Systems and methods for clonal expression in plants |
| US7306807B2 (en) | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
| JP4994241B2 (ja) * | 2004-11-22 | 2012-08-08 | ニューヨーク・ユニバーシティ | 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用 |
| WO2007042884A1 (en) | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Vaccines and methods to treat canine influenza |
| DK1931379T3 (da) | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
| CN101849013A (zh) * | 2007-05-30 | 2010-09-29 | 惠氏有限责任公司 | 猫抗原的浣熊痘病毒表达基因 |
| US8445650B2 (en) * | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
| WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| DK2948174T3 (da) | 2013-01-28 | 2019-12-02 | Univ New York | Fremgangsmåder til behandling under anvendelse af atoksiske neurotoksinderivater |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11897921B2 (en) | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
| AU2018389121A1 (en) | 2017-12-20 | 2020-07-30 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| AU695623B2 (en) * | 1994-05-31 | 1998-08-20 | Allergan, Inc. | Modification of clostridial toxins for use as transport proteins |
| BR9509903A (pt) * | 1994-10-24 | 1997-11-25 | Ophidian Pharm Inc | Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial |
| WO1996040229A1 (en) * | 1995-06-07 | 1996-12-19 | Thomas Jefferson University | Vaccines synthesized by transgenic plants |
| WO1997032599A1 (en) * | 1996-03-08 | 1997-09-12 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
-
1997
- 1997-10-20 US US08/954,302 patent/US6051239A/en not_active Expired - Fee Related
-
1998
- 1998-10-16 EP EP98953617A patent/EP1024827B1/en not_active Expired - Lifetime
- 1998-10-16 EE EEP200000536A patent/EE200000536A/xx unknown
- 1998-10-16 NZ NZ504549A patent/NZ504549A/xx unknown
- 1998-10-16 RU RU2000112547/15A patent/RU2227042C2/ru not_active IP Right Cessation
- 1998-10-16 CA CA002306995A patent/CA2306995A1/en not_active Abandoned
- 1998-10-16 HU HU0101017A patent/HUP0101017A3/hu unknown
- 1998-10-16 JP JP2000516701A patent/JP2001522783A/ja active Pending
- 1998-10-16 AT AT98953617T patent/ATE355076T1/de not_active IP Right Cessation
- 1998-10-16 IL IL13574398A patent/IL135743A/en not_active IP Right Cessation
- 1998-10-16 WO PCT/US1998/021897 patent/WO1999020306A1/en not_active Ceased
- 1998-10-16 KR KR1020007004197A patent/KR100594787B1/ko not_active Expired - Fee Related
- 1998-10-16 DE DE69837209T patent/DE69837209T2/de not_active Expired - Fee Related
- 1998-10-16 AU AU10947/99A patent/AU756475B2/en not_active Ceased
- 1998-10-16 BR BR9815255-6A patent/BR9815255A/pt not_active Application Discontinuation
- 1998-10-16 CN CNB988112981A patent/CN1246038C/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001522783A5 (enExample) | ||
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| WO1996020734A3 (en) | Oral gastrointestinal x-ray contrast agents in combination with pharmaceutically acceptable clays and surfactants | |
| HRP20030951B1 (hr) | Formulacije jednodnevnih doza oksikodona | |
| HRP20020088B1 (hr) | Levodopa/karbidopa/entakapon farmaceutski pripravak | |
| AU4425496A (en) | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays | |
| DE60003160D1 (de) | Kombinationen von formoterol und mometasonfuroat | |
| JO3404B1 (ar) | تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين | |
| JP2002528502A5 (enExample) | ||
| JP2005508338A5 (enExample) | ||
| SE8801732L (sv) | Ny komposition | |
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| JP2002522501A5 (enExample) | ||
| HU9302970D0 (en) | Swallowable prepartions for the treatment of pains of superior gastrointestinal tracts | |
| CA2032475A1 (en) | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | |
| EP1431286A3 (en) | Prodigiosin derivatives for treating cancer or viral diseases | |
| JP2003514025A5 (enExample) | ||
| CA2354039A1 (en) | Pharmaceutical formulations in hydroxypropylmethylcellulose capsules | |
| NO20042011L (no) | Fremgangsmate ved fremstilling av en farmasoytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom | |
| ES2286471T3 (es) | Composiciones farmaceuticas antivirales. | |
| EG24584A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of uicerative colitis and crohn's disease | |
| DE69715148D1 (de) | Pharmazeutische Zusammensetzungen mit Laktobazillen zur transmucosalen Verabreichung | |
| HUP0102388A3 (en) | Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease | |
| JP2002326936A5 (enExample) |